Immunic Inc (NASDAQ:IMUX) will present data from its phase 2 EMPhASIS trial of vidofludimus calcium in multiple sclerosis at the 9th Joint ECTRIMS-ACTRIMS Meeting in Milan, Italy, and will also participate in the United European Gastroenterology Week 2023 in Copenhagen, presenting on treatments for celiac disease and ulcerative colitis. Additionally, Immunic's Head of Regulatory Affairs will speak at the Global Pharmaceutical Regulatory Affairs Summit in Brussels, Belgium, addressing topics on clinical trials regulation and the future of legislation and regulatory affairs.
The Markets by Proactive
Go to Proactive UK
Proactive’s coverage of London’s small caps continues on .com